Angiotensin II type 1a receptor loss ameliorates chronic tubulointerstitial damage after renal ischemia reperfusion.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 01 2021
13 01 2021
Historique:
received:
15
08
2020
accepted:
14
12
2020
entrez:
14
1
2021
pubmed:
15
1
2021
medline:
13
8
2021
Statut:
epublish
Résumé
We investigate whether suppressing the activation of the angiotensin II type 1a receptor (AT1a) can ameliorate severe chronic tubulointerstitial damage (TID) after renal ischemia reperfusion (IR) using AT1a knockout homozygous (AT1a
Identifiants
pubmed: 33441837
doi: 10.1038/s41598-020-80209-0
pii: 10.1038/s41598-020-80209-0
pmc: PMC7806698
doi:
Substances chimiques
Receptor, Angiotensin, Type 1
0
Angiotensin II
11128-99-7
Hydralazine
26NAK24LS8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
982Références
JCI Insight. 2016 Jul 21;1(11):e87680
pubmed: 27699223
Nephron Exp Nephrol. 2014;126(4):183-90
pubmed: 24993481
Nat Rev Nephrol. 2011 Oct 18;7(12):684-96
pubmed: 22009250
Kidney Int. 2016 Feb;89(2):363-73
pubmed: 26509589
Sci Rep. 2016 Sep 28;6:34265
pubmed: 27677327
N Engl J Med. 2014 Jul 3;371(1):58-66
pubmed: 24988558
Lancet. 2013 Jul 13;382(9887):158-69
pubmed: 23727165
Kidney Int. 2017 Jan;91(1):157-176
pubmed: 27692563
Eur J Anaesthesiol. 2018 Apr;35(4):273-279
pubmed: 29210843
Kidney Int. 1998 Apr;53(4):937-44
pubmed: 9551401
Am J Physiol Renal Physiol. 2020 Oct 1;319(4):F563-F570
pubmed: 32799675
PLoS One. 2017 Feb 9;12(2):e0171868
pubmed: 28182761
J Am Soc Nephrol. 2016 Aug;27(8):2257-64
pubmed: 26744488
Kidney Int. 2014 Jul;86(1):75-85
pubmed: 24429402
J Clin Invest. 2014 May;124(5):2198-203
pubmed: 24743144
Clin J Am Soc Nephrol. 2008 Sep;3(5):1266-73
pubmed: 18667735
J Am Soc Nephrol. 2009 Jan;20(1):223-8
pubmed: 19020007
Semin Nephrol. 2019 Nov;39(6):581-588
pubmed: 31836040
Biomarkers. 2017 Feb;22(1):5-13
pubmed: 27028054
FASEB J. 2017 Jan;31(1):72-84
pubmed: 27663860
Anesthesiology. 2017 Jan;126(1):47-65
pubmed: 27792044
Hypertension. 1995 May;25(5):924-7
pubmed: 7737728
Am J Physiol. 1997 Apr;272(4 Pt 2):F515-20
pubmed: 9140053
Life Sci. 2015 Mar 1;124:81-90
pubmed: 25623850
J Am Soc Nephrol. 2016 Jun;27(6):1727-40
pubmed: 26453613
Br J Pharmacol. 2018 Jul;175(13):2689-2708
pubmed: 29679507
J Biol Chem. 1995 Aug 11;270(32):18719-22
pubmed: 7642517
Am J Physiol Renal Physiol. 2014 Mar 15;306(6):F655-63
pubmed: 24431207
Am J Physiol Renal Physiol. 2015 Feb 15;308(4):F358-65
pubmed: 25411386
Eur J Pharmacol. 2017 Nov 15;815:88-97
pubmed: 28888756
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Am J Kidney Dis. 2013 Dec;62(6):1077-86
pubmed: 23791246
Sci Rep. 2019 Dec 5;9(1):18445
pubmed: 31804508
N Engl J Med. 1996 Jan 4;334(1):13-8
pubmed: 7494564
Kidney Int. 2012 Feb;81(4):351-62
pubmed: 22166846
Nephrology (Carlton). 2018 Apr;23(4):308-316
pubmed: 28063188
Clin J Am Soc Nephrol. 2020 Jan 7;15(1):26-34
pubmed: 31843974
J Am Soc Nephrol. 2007 Jun;18(6):1928-35
pubmed: 17475822
Sci Rep. 2017 Apr 13;7:46518
pubmed: 28406186
J Am Soc Nephrol. 2015 Aug;26(8):1765-76
pubmed: 25810494
J Am Soc Nephrol. 1997 Nov;8(11):1658-67
pubmed: 9355068
Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1187-95
pubmed: 25350978
Biosci Rep. 2019 Apr 9;39(4):
pubmed: 30877184
Nephron Exp Nephrol. 2009;112(1):e10-9
pubmed: 19342869
BMC Nephrol. 2016 Sep 29;17(1):136
pubmed: 27682843
Intensive Care Med. 2018 May;44(5):598-605
pubmed: 29766216